LEADER 04638nam 22006975 450 001 9910300214403321 005 20200701215654.0 010 $a3-319-17467-3 024 7 $a10.1007/978-3-319-17467-9 035 $a(CKB)3710000000416808 035 $a(EBL)2094728 035 $a(SSID)ssj0001501430 035 $a(PQKBManifestationID)11896721 035 $a(PQKBTitleCode)TC0001501430 035 $a(PQKBWorkID)11524765 035 $a(PQKB)10739438 035 $a(DE-He213)978-3-319-17467-9 035 $a(MiAaPQ)EBC2094728 035 $a(PPN)186026498 035 $a(EXLCZ)993710000000416808 100 $a20150527d2015 u| 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 10$aDiagnosis and Management of Testicular Cancer $eThe European Point of View /$fedited by Susanne Krege 205 $a1st ed. 2015. 210 1$aCham :$cSpringer International Publishing :$cImprint: Springer,$d2015. 215 $a1 online resource (136 p.) 300 $aDescription based upon print version of record. 311 $a3-319-17466-5 320 $aIncludes bibliographical references. 327 $aPart I: Overview of the latest recommendations of the European Germ Cell Cancer Group -- Part II: Special topics about controversial aspects, new results from studies, which might change treatment recommendations and long-term-survivorship: Is there still an indication for radiotherapy in seminoma CS I/ IIA/B?- How should we treat nonseminoma CSI? -- Is there still an indication for diagnostic RPLND in nonseminoma CSI? -- How could the prognosis of patients with intermediate risk disease be improved? -- How should patients with poor-prognosis disease be treated actually? -- How should patients with recurrent disease be treated actually? -- How important are prognostic factors for determining treatment in patients with primary or recurrent disease? -- What should be the boundaries in retroperitoneal residual tumor resection in nonseminoma? -- How should residual disease outside the retroperitoneum be treated? -- What are the recent recommendations for follow up in testicular cancer? -- What are the long-term toxicities to be controlled and treated? -- Consequences of the disease and its treatment concerning sexuality and fertility. 330 $aThis book presents the views of leading European experts on the diagnosis and management of testicular cancer, with coverage of current hot topics in the field. It opens by providing an overview of the recommendations in the most recent consensus paper from the European Germ Cell Cancer Consensus Group, which is based on interdisciplinary cooperation among urologists, medical oncologists, radio-oncologists, pathologists, and basic scientists. The remainder of the book focuses on areas of controversy in the diagnosis, treatment, and follow-up of testicular cancer. In each case the evidence base is discussed and results from the most recent studies are reviewed, drawing attention to new findings that might alter treatment recommendations. The treatment-related chapters cover a broad range of issues, including the best approach in patients with poor-prognosis and recurrent disease and those with long-term toxicities. Relevant aspects of survivorship care are also addressed. The book will help clinicians and practitioners to achieve the goals of minimizing therapy and its side-effects without reducing efficacy in low stage disease, improving the cure rate in advanced disease, and enhancing follow-up and long-term survivorship. 606 $aOncology   606 $aUrology 606 $aSurgery 606 $aRadiotherapy 606 $aOncology$3https://scigraph.springernature.com/ontologies/product-market-codes/H33160 606 $aUrology$3https://scigraph.springernature.com/ontologies/product-market-codes/H62002 606 $aSurgery$3https://scigraph.springernature.com/ontologies/product-market-codes/H59001 606 $aRadiotherapy$3https://scigraph.springernature.com/ontologies/product-market-codes/H29056 615 0$aOncology  . 615 0$aUrology. 615 0$aSurgery. 615 0$aRadiotherapy. 615 14$aOncology. 615 24$aUrology. 615 24$aSurgery. 615 24$aRadiotherapy. 676 $a610 676 $a615842 676 $a616.6 676 $a616994 676 $a617 702 $aKrege$b Susanne$4edt$4http://id.loc.gov/vocabulary/relators/edt 906 $aBOOK 912 $a9910300214403321 996 $aDiagnosis and Management of Testicular Cancer$91761302 997 $aUNINA